Prevention and treatment of acute GvHD
Prevention and treatment of acute GvHD
复制标题
DOI：
10.1038/bmt.2008.57
复制
发表时间：
2008-06-01
影响因子：
4.8
通讯作者：
Calore, E.
中科院分区：
文献类型：
--
作者：
Messina, C.;Faraci, M.;Calore, E.
GvHD仍然是异基因造血SCT中显著发病率和死亡率的来源。改善干细胞移植受者的结局需要额外的GvHD治疗方式，特别是对于对类固醇初始治疗无效的患者。此外，虽然没有急性GvHD（aGvHD）与潜在恶性疾病复发的较高风险相关，但严重的aGvHD通常诱导危及生命的并发症如严重感染的发生。本文就aGvHD的预防和治疗现状作一综述。
GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.